Product
BG505 SOSIP.664 gp140 Vaccine
2 clinical trials
1 indication
Indication
HIVClinical trial
An Open-Label Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults in Good General Health Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, AdjuvantedStatus: , Estimated PCD: 2025-03-01
Clinical trial
An Open-Label Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults in Good General Health Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, AdjuvantedStatus: Not yet recruiting, Estimated PCD: 2024-03-01